Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY
Alnylam Pharmaceuticals — Technical Presentation (July 2021)
69 slides from Alnylam Pharmaceuticals's technical presentation, Jul 16, 2021
Slide 1: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis
Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis July 16, 2021 1 © 2021 Alnylam Pharmaceuticals, Inc.
Slide 2: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 3: Reminders
Reminders Event will run for approximately 60 - 75 minutes Q&A session at end of presentation • Questions may be submitted at any time via the ‘Ask a Question’ field on the webcast interface Replay, slides and transcript available at www.alnylam.com/capella 3
Slide 4: Alnylam Forward Looking Statements
Alnylam Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including expectations regarding our aspiration to become a leading biotech company, and th
Slide 5: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 6: RNAi Therapeutics: New Class of Innovative Medicines
RNAi Therapeutics: New Class of Innovative Medicines Clinically and Commercially Established Approach with Transformational Potential Nobel Prize-winning science Silence any gene in genome with siRNAs Potent and durable mechanism of action Product engine for sustainable innovation Multiple products
Slide 7: Alnylam P5x25 Goals
Patients: Over 0.5 million on Alnylam RNAi therapeutics globally Products: 6+ marketed products in rare and prevalent diseases Pipeline: Over 20 clinical programs, with 10+ in late stages and 4+ INDs per year Performance: ≥40% revenue CAGR through YE 2025 Profitability: Achieve sustainable non-GAAP
Slide 8: Additional Alnylam and Partner Launches Planned Over Next 12-24 Months
Additional Alnylam and Partner Launches Planned Over Next 12-24 Months Compelling Commercial Profile of Existing and Emerging Medicines 2018 2019 2020 2020 2022-2023 Leqvio® Vutrisiran Fitusiran* (inclisiran) ONPATTRO is indicated in the GIVLAARI is indicated in the OXLUMO is indicated in the Leqvio
Slide 9: Alnylam Clinical Development Pipeline
Alnylam Clinical Development Pipeline Focused in 4 Strategic Therapeutic Areas (STArs): Genetic Medicines Cardio-Metabolic Diseases EARLY/MID-STAGE LATE STAGE REGISTRATION/ COMMERCIAL (IND/CTA Filed-Phase 2) (Phase 2-Phase 3) COMMERCIAL1 RIGHTS Infectious Diseases CNS/Ocular Diseases (OLE/Phase 4/II
Slide 10: Alnylam Clinical Development Pipeline
Alnylam Clinical Development Pipeline Focused in 4 Strategic Therapeutic Areas (STArs): Genetic Medicines Cardio-Metabolic Diseases EARLY/MID-STAGE LATE STAGE REGISTRATION/ COMMERCIAL (IND/CTA Filed-Phase 2) (Phase 2-Phase 3) COMMERCIAL1 RIGHTS Infectious Diseases CNS/Ocular Diseases (OLE/Phase 4/II
Slide 11: ATTR Amyloidosis
ATTR Amyloidosis Rare, Progressively Debilitating, and Fatal Disease Description Caused by misfolded TTR protein that accumulates as amyloid deposits in multiple GI: Diarrhea tissues including heart, nerves, and GI tract1 Nausea Vomiting CARDIAC: GU: Hereditary ATTR (hATTR) Amyloidosis Heart failure
Slide 12: A Patient Story
A Patient Story Diagnosed with hATTR Amyloidosis with Polyneuropathy Dawn Caregiver and Patient “With therapies now available, and more in clinical development, the trauma of chronic illness and loss ends with me, and my family and I can be hopeful for the future.” 12
Slide 13: RNAi Therapeutic Hypothesis in ATTR Amyloidosis
RNAi Therapeutic Hypothesis in ATTR Amyloidosis Silencing TTR Gene Expression Can Potentially Address Underlying Cause of Disease Production of mutant and wild-type TTR in liver* Reduce circulating TTR Prevent or clear PATISIRAN / VUTRISIRAN tissue amyloid deposits siRNA sequences selected to silenc
Slide 14: Current or Potential Therapy Options for ATTR Amyloidosis
Current or Potential Therapy Options for ATTR Amyloidosis RNAi Therapeutics Work by Silencing the Source of Disease ATTR Amyloidosis Disease Cascade and Current/Potential Therapies Proteolysis and dissociation Misfolding Aggregation Deposition TTR gene expressed in liver TTR tetramer TTR fragments M
Slide 15: Alnylam's ATTR Amyloidosis Franchise
Alnylam’s ATTR Amyloidosis Franchise Approved Treatment Option, Investigational Clinical Programs, and a Preclinical Development Program Vutrisiran ALN-TTRsc04 An Approved RNAi Therapeutic for An Investigational RNAi A Preclinical RNAi Therapeutic for Treatment of Polyneuropathy of Therapeutic for P
Slide 16: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 17: Vutrisiran Phase 3 HELIOS-A Study Design
Vutrisiran Phase 3 Study Randomized, Open-label Study in Patients with hATTR Amyloidosis with Polyneuropathy • Presenting 9-month primary efficacy analysis compared with the external placebo group (placebo arm of APOLLO) selected on the basis of similar patient populations and endpoints n=122 9-Mont
Slide 18: Baseline Demographic and Disease Characteristics
Baseline Demographic and Disease Characteristics APOLLO HELIOS-A Characteristic Placebo Vutrisiran Patisiran n=77 n=122 n=42 Age (years), median (range) 63 (34, 80) 60 (26, 85) 60 (31, 81) Males, n (%) 58 (75) 79 (65) 27 (64) TTR genotype, n (%) V30M 40 (52) 54 (44) 20 (48) Non-V30M 37 (48) 68 (56)
Slide 19: Significant Improvement in Neuropathy Impairment with Vutrisiran
Significant Improvement in Neuropathy Impairment with Vutrisiran • Vutrisiran achieved statistically significant improvement in mNIS+7 at 9 months, compared with the external placebo group – Improvements across all pre-specified patient subgroups* and components of mNIS+7 (data not shown) 20 mNIS+7
Slide 20: Significant Improvement in Quality of Life with Vutrisiran
Significant Improvement in Quality of Life with Vutrisiran • Vutrisiran achieved statistically significant improvement in Norfolk QOL-DN at 9 months, compared with the external placebo group – Improvements across all pre-specified patient subgroups* and domains of Norfolk QOL-DN (data not shown) 20
Slide 21: Significant Improvement in Gait Speed with Vutrisiran
Significant Improvement in Gait Speed with Vutrisiran • Vutrisiran achieved statistically significant improvement in gait speed measured by 10-MWT at 9 months, compared with the external placebo group 10-MWT LS Mean Change from Baseline* 0.05 –0.001 (0.019) Better n=113† n=122† Vutrisiran (HELIOS-A)
Slide 22: Treatment Effects Observed in Vutrisiran Were Consistent With Patisiran in APOLLO
Treatment Effects Observed in Vutrisiran Were Consistent With Patisiran in APOLLO Post Hoc Cross-Study Assessment of LS Mean Change From Baseline to 9 Months for Endpoints for Vutrisiran and APOLLO Patisiran Arm HELIOS-A APOLLO Vutrisiran Patisiran (n=122) Vutrisiran – Placebo (n=148) Patisiran – Pl
Slide 23: Improvement in Neurologic Impairment and Quality of Life in Majority of Patients
Improvement in Neurologic Impairment and Quality of Life in Majority of Patients Receiving Vutrisiran Percent of Patients Achieving Improvement in mNIS+7* and Norfolk QOL-DN* at Month 9 100 Improvement in mNIS+7 Improvement in Norfolk QOL-DN Odds ratio (95% CI): 4.8 (2.4, 9.5) Odds ratio (95% CI): 4
Slide 24: Exploratory Endpoints at 9 Months, Including NT-proBNP
Exploratory Endpoints at 9 months, Including NT-proBNP, Demonstrated Improvements Compared with the External Placebo Group Change from Baseline in NT-proBNP Change from Baseline in NT-proBNP (mITT Population)* (Cardiac Subpopulation)† 2 2 1.59 1.60 n=65‡ Adjusted Geometric Fold Change n=30‡ Adjusted
Slide 25: Rapid and Sustained Reduction in Serum TTR Levels with Vutrisiran
Rapid and Sustained Reduction in Serum TTR Levels with Vutrisiran Similar to Patisiran in HELIOS-A • Vutrisiran achieved a mean steady-state* serum TTR reduction from baseline of 83% (SD: 14%), with maximum observed reduction of 98% Percent Change from Baseline in Serum TTR Levels* 0 Vutrisiran (HEL
Slide 26: HELIOS-A Safety Summary
HELIOS-A Safety Summary* Acceptable Safety Profile of Vutrisiran HELIOS-A Safety Summary*,† The majority of AEs were mild or moderate in severity • No drug-related discontinuations or deaths APOLLO† HELIOS-A • Two study discontinuations (1.6%) due to AEs in the vutrisiran Placebo Vutrisiran Patisira
Slide 27: HELIOS-A 18-Month Data to Further Assess Vutrisiran
HELIOS-A 18-Month Data to Further Assess Vutrisiran 18-Month Results Expected Late 2021 Additional Secondary Endpoints • Extend mNIS+7, Norfolk QOL, and 10-MWT dataset beyond 9 months with longer follow-up • Assess new secondary endpoints: mBMI, R-ODS, serum TTR reduction Exploratory Endpoints • Fur
Slide 28: Opportunity for q6M Vutrisiran Dosing Regimen
Opportunity for q6M Vutrisiran Dosing Regimen Modeling Supports Potential Biannual 50mg Dosing Regimen in Addition to Quarterly 25mg Dosing Regimen Phase 1 Study – Healthy Volunteers Pharmacodynamic Modeling • Mean max TTR reduction of >80% after single dose of • After repeat dosing, ~90% peak TTR r
Slide 29: Vutrisiran Phase 3 HELIOS-A Study
Vutrisiran Phase 3 Study Randomized, Open-Label Study in Hereditary ATTR Amyloidosis Patients with Polyneuropathy Randomized Treatment N=122 9-Month Efficacy Extension (RTE) Assessment Patient Population Vutrisiran N=164 Vutrisiran vs APOLLO Placebo Vutrisiran 3:1 RANDOMIZATION 25 mg • 18–85 years o
Slide 30: Vutrisiran Key Milestones and Planned Next Steps
Vutrisiran Key Milestones and Planned Next Steps Regulatory Submissions EU, BR, JP Late 2021 HELIOS-A Topline 18-Month Results Late 2021 If Approved, U.S. Launch Early 2022 50mg q6M Data Readout Late 2022 30
Slide 31: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 32: Patisiran Post-OLT Study Design
Patisiran Post-OLT Study Design Phase 3b, Open-Label Study Conducted across Several European Countriesa Patient population (n=23) Primary endpoint: • Age ≥18 years • Average of Month 6 and Month 12 TTR percent reduction • Received OLT for hATTR amyloidosis ≥12 months prior to study start Secondary e
Slide 33: Baseline Demographics and Characteristics
Baseline Demographics and Characteristics Baseline demographics and characteristics Safety analysis set (n=23) Age, years, mean (SD) 58.1 (9.9) Male, n (%) 13 (56.5) • Patients received an OLT an average of 3.7 years after Race, n (%) White 22 (95.7) diagnosis Asian 1 (4.3) • On average, patients re
Slide 34: Rapid and Sustained Reduction in Serum TTR Levels with Patisiran
Rapid and Sustained Reduction in Serum TTR Levels with Patisiran Primary Endpoint • Median (95% CI) TTR percent reduction from baseline (average of Month 6 and Month 12) was 91.0 (86.1, 92.3) 20 Percent Change in TTR through Month 12a Mean (±SEM) Change in TTR Levels, % n=23 0 -20 -40 -60 n=22 -80 n
Slide 35: Improvement in Polyneuropathy Disease Manifestations with Patisiran
Improvement in Polyneuropathy Disease Manifestations with Patisiran Secondary Endpoints at Month 12 • Improvement in neuropathy, as demonstrated by a decrease in mean total NIS from baseline 5 Total NIS Mean Change from Baselinea NIS Mean (±SEM) Change from Baseline Worse 0 -5 –0.4 (3.3) Better –3.7
Slide 36: Patisiran Post-OLT: Summary of Safety
Patisiran Post-OLT: Summary of Safety Majority of AEs Were Mild or Moderate Safety analysis set Patients with ≥1 event, n (%) (n=23) • Common adverse events (AEs) were consistent with those seen Any AE 23 (100) in the Phase 3 APOLLO study1 – The most common AE was diarrhea (34.8%) AEs reported in ≥1
Slide 37: Patisiran Phase IV Observational Study
Patisiran Phase IV Observational Study A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of hATTR Amyloidosis with a V122I or T60A Variant N = 68 Primary endpoint Patient Population: ➢ Proportion of patients with stable or • hATTR amyloidosi
Slide 38: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 39: Alnylam RNAi Roundtable: ATTR amyloidosis
Alnylam RNAi Roundtable: ATTR amyloidosis Mat Maurer, MD Columbia University Medical Center Arnold and Arlene Goldstein Professor of Cardiology July 16th, 2021 39
Slide 40: Disclosures
Disclosures • I have consulted for and/or received support from several sources for my research: – NIH/NIA/NHLBI -Eidos – GSK -Prothena – Akcea, Inc -Ionis Pharmaceuticals – Alnylam Pharmaceuticals, Inc -Pfizer, Inc. – Abbott, Inc -Intellia 40
Slide 41: Two Main Types of Cardiac Amyloidosis
Two Main Types of Cardiac Amyloidosis • Differences in – Precursor Protein / Biology – Natural History / Prognosis – Genetics – Treatment Cleveland Clin. J. Med. 84(12 Suppl. 3):12–26 41 Circulation. 2017;135(14):1357-1377
Slide 42: Different Types of Cardiac Amyloidosis
Different Types of Cardiac Amyloidosis Features AL ATTRh ATTRwt Epidemiology Average at diagnosis 5th to 9th decade 3rd to 8th decade 7th to 10th decade Gender Equal male and female Male predominance 80-90% Males Biology Precursor protein Light chain Mutant TTR TTR Genetic cause None Autosomal domin
Slide 43: Multi-systemic Disease with Significant Risk of Misdiagnosis and Delayed Diagnosis
Multi-systemic Disease with Significant Risk of Misdiagnosis and Delayed Diagnosis • 75% saw > 3 physicians before diagnosis made • 63% > 6 months to diagnosis • 44% received an incorrect diagnosis first • 31% required air travel to establish diagnosis • Only 18% of these patients with cardiac AL ha
Slide 44: Diagnostic Tests and Their Role in Evaluation and Management of Cardiac Amyloidosis
Diagnostic Tests and Their Role in the Various Phases of Evaluation and Management of Cardiac Amyloidosis 44 Circulation. 2017;135:1357–1377.
Slide 45: Advantages, Limitations and Novel Insights of Imaging Modalities
Advantages, Limitations and Novel Insights of Imaging Modalities 45 Canadian Journal of Cardiology 32(9) 2016, 1166.e1-1166.e10
Slide 46: Discordance Between Voltage/Wall Thickness
Discordance Between Voltage /Wall Thickness Males Females Total QRS/LVWT: Males, cutoff 8.4; Females, cutoff 7.7 Total QRS/LVWT/h2.7: Males, cutoff 36.4; Female, cutoff 27.3 46
Slide 47: Leveraging AI and Machine Learning to Facilitate a Diagnosis of Cardiac Amyloidosis
Leveraging AI and Machine Learning to Facilitate a Diagnosis of Cardiac Amyloidosis AUC P Model (95% CI) value Total QRS Score 0.80 <0.001 (Quarta et al) (0.74-0.87) 0.88 EKG Features Only <0.001 (0.84-0.93) EKG Features + 0.945 <0.001 LV Thickness (0.91-0.98) LV Poster Wall 0.85 <0.001 Thickness On
Slide 48: Pathogenesis of ATTR Amyloidosis
Pathogenesis of ATTR Amyloidosis Multiple Manifestations of One Disease 48 Slide courtesy of Jeff Kelly, PhD
Slide 49: Approved and Investigational Therapies for Transthyretin Amyloidosis
Approved and Investigational Therapies for Transthyretin Amyloidosis have Emerged from Elucidation of Underlying Biology TTR Silencing/ TTR Stabilizers Anti-Amyloid Therapies Knockdown Tafamidis PRX004 Diflunisal NI006 ASOs AG10 CAEL-101 siRNAs AT-03 CRISPR JACC. 2019;73(22):2872-2891. Currently sil
Slide 50: While Tafamidis Reduces All-cause Mortality and CV Hospitalizations, Significant Unmet Need Remains
While Tafamidis Reduces All-cause Mortality and CV Hospitalizations, Significant Unmet Patient Need Remains in ATTR 30% reduction (P=0.026) in overall mortality with tafamidis compared to placebo (need to treat 7-8 patients to prevent one death over 2 ½ years). However, 3 out of 10 tafamidis-treated
Slide 51: Tafamidis Reduced Decline in Functional Capacity & QOL, Unmet Need Remains
While Tafamidis Reduced the Decline in Functional Capacity & QOL Relative to Placebo, the Average Patient didn’t Feel or Function Better than at Baseline Based on 6MWT/KCCQ-OS - Pointing Again to Significant Unmet Need in ATTR Amyloidosis 51 Maurer MS, et al. N Engl J Med. 2018 Aug 27.
Slide 52: Earlier Treatment in ATTR-CM Affects Patient Outcomes
Earlier Treatment in ATTR-CM Affects Patient Outcomes This slide to be created by Terri (placeholder only) Maurer MS, et al. N Engl J Med. 2018 Aug 27. 52
Slide 53: Expert Consensus on Monitoring of Disease Progression
Expert Consensus on Monitoring of Disease Progression 53 European Journal of Heart Failure (2021) doi:10.1002/ejhf.2198
Slide 54: Expert Consensus on Monitoring of Disease Progression
Expert Consensus on Monitoring of Disease Progression 54 European Journal of Heart Failure (2021) doi:10.1002/ejhf.2198
Slide 55: Summary
Summary • Emerging therapies for ATTR amyloidosis have been developed from translational research which has elucidated biologic mechanisms. • A large portion of patients with ATTR amyloidosis remain undiagnosed and the diagnosis continues to be made in late stage patients. • Patients and clinicians
Slide 56: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 57: Evidence for Investigational RNAi Therapeutics in ATTR Cardiomyopathy
Evidence for Investigational RNAi Therapeutics in ATTR Cardiomyopathy1 Exploratory & Post-hoc Data from APOLLO2 Investigator-Sponsored Study from National Amyloidosis Centre, UK3 Composite Rate of All-Cause Hospitalization and Mortality2,4 • 55% Relative reduction in NT-proBNP vs. placebo2,† Patient
Slide 58: Patisiran Phase 3 APOLLO-B Study
Patisiran Phase 3 Study Randomized, Double-Blind, Placebo-Controlled Study in ATTR Amyloidosis Patients with Cardiomyopathy N ~ 300 Primary Endpoint Patient Population Patisiran • Change in 6-MWT at 12 months IV q3w† 1:1 RANDOMIZATION • ATTR amyloidosis; wild-type or 0.3 mg/kg any TTR mutation Key S
Slide 59: Vutrisiran Phase 3 HELIOS-B Study
Vutrisiran Phase 3 Study Randomized, Double-Blind Outcomes Study in ATTR Amyloidosis Patients with Cardiomyopathy Primary Endpoint N ~ 600 • Composite outcome of all-cause mortality and recurrent CV events (when Vutrisiran last patient reaches Month 30) Patient Population SC q3M 1:1 RANDOMIZATION •
Slide 60: Optional HELIOS-B Interim Analysis
Optional HELIOS-B Interim Analysis Evaluating Options for Potential Readout Before Last Patient Reaches Month 30 • Optional interim analysis included in protocol – Details not specified • Engagement with regulatory authorities to align on a potential approach • Staging after APOLLO-B data readout in
Slide 61: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 62: Key Drivers of Potential Market Expansion with Vutrisiran
Key Drivers of Potential Market Expansion with Vutrisiran* CLINICAL EFFICACY Reversed neuropathy impairment of Building on ONPATTRO foundation, disease in majority of HELIOS-A patients vutrisiran has potential to become treatment of choice in hATTR amyloidosis with polyneuropathy PATIENT CHOICE Addr
Slide 63: IKARIA Platform and Preclinical ALN-TTRsc04
IKARIATM Platform and Preclinical ALN-TTRsc04 Multidose Modeling • Continued innovation in RNAi Based on NHP Data with therapeutics ALN-TTRsc04 Supports Annual Dosing • Extended duration platform with potential for once annual dosing – long-acting and reversible • Potential for highly potent knockdo
Slide 64: Alnylam ATTR Amyloidosis Franchise
Alnylam ATTR Amyloidosis Franchise Potential to Expand Value to Patients Globally for Many Years to Come Novel siRNA Conjugates^ Ocular & CNS hATTR Amyloidosis ALN-TTRsc04 ATTR Amyloidosis Patisiran Vutrisiran C CM (including Wild-Type)‡ Early ATTR Amyloidosis† Biannual Dosing Vutrisiran Vutrisiran
Slide 65: Building Leading ATTR Franchise to Serve Patients for Years to Come
Building Leading ATTR Franchise to Serve Patients for Years to Come Vision: ONPATTRO® Establishes Strong Foundation; Vutrisiran Achieves Sustainable Market Leadership Benefits of franchise Patient and physician choice is key Product revenue supports continued investment Alnylam aims to provide multi
Slide 66: Pictures of our patients
Pictures of our patients (different from last year) 66
Slide 67: Agenda
Agenda Welcome • Joshua Brodsky, Senior Director, Investor Relations & Corporate Communications Introduction and Overview of ATTR Amyloidosis • Rena Denoncourt – Vice President, ATTR Amyloidosis Franchise Lead • Patient Story – Dawn, caregiver and hATTR amyloidosis patient Recent Vutrisiran Clinical
Slide 68: Upcoming RNAi Roundtables
Upcoming RNAi Roundtables Givosiran, for the Treatment of Acute Hepatic Porphyria • Wednesday, August 4, 1:30 pm ET Additional details for upcoming RNAi Roundtables, including speakers, dates and times, will be provided on the Capella section of the Company’s website, www.alnylam.com/capella 68
Slide 69: Challenge Accepted
To those who say “impossible, impractical, unrealistic,” we say: CHALLENGE ACCEPTED 69 © 2021 Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals — Technical Presentation (July 2021) on 6ix